Researchers at Changzhou Hengbang Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described polypeptides acting as C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of cancer, infections, cardiovascular disorders, endocrine disorders and immunological disorders.
Hangzhou Baicreat Pharma-Tech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.
Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Apollo AP45 Ltd. has described eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitors reported to be useful for the treatment of cancer.
Nanjing Minova Pharmaceutical Co. Ltd. and Precision Brain Science Biotechnology (Suzhou) Co. Ltd. have identified salts of deuterated dextromethorphan reported to be useful for the treatment of cough, pain, epilepsy, cancer, rheumatoid arthritis, dermatitis, cardiovascular disorders and glaucoma.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized aza-tricyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shenzhen Targetrx Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a Bcr-Abl (Bcr-Abl1) kinase and its mutant targeting moiety through a linker reported to be useful for the treatment of cancer and immunological disorders.
RSS